US Pharma MarketingUltragenyx’s Angelman therapy fails Phase 3 trial in setback for company and patients
Ultragenyx Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals: What’s changing…
In a major setback to the search for a treatment for the rare neurodevelopmental disease known as Angelman syndrome, Ultragenyx said a Phase 3 trial of its experimental therapy failed.
The company's antisense oligonucleotide therapy ...
Source: Endpoints News